Another 2nd generation ALK inhibitor, Alectinib, has been approved for first-line treatment of advanced ALK-positive NSCLC due to its superior activity in the CNS and that it may overcome resistance to Crizotinib. Here, ALK is linked to non-small cell lung carcinoma.